CorMedix Acquires Melinta Therapeutics for $300 Million
August 7, 2025
CorMedix Inc. has entered into a definitive agreement to acquire Melinta Therapeutics, paying $300 million upfront (including $260 million cash and $40 million in CorMedix equity to Melinta shareholders), plus up to $25 million in a regulatory milestone and tiered royalties. The deal is expected to close in September, subject to customary closing conditions and U.S. regulatory approval.
- Buyers
- CorMedix Inc.
- Targets
- Melinta Therapeutics, LLC
- Sellers
- Affiliates of Deerfield Management Company, L.P.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.